Investment Thesis
Cero Therapeutics is a pre-revenue biotech company in severe financial distress with negative stockholders' equity of -4.5M, indicating liabilities exceed assets. The company is burning cash at -1.5M annually with only 1.9M in cash reserves, providing less than 18 months of runway, while demonstrating a catastrophic ROA of -393.2% and inability to cover operating costs.
Strengths
- Recent improvement in net loss (26.5% YoY reduction)
- Moderate insider activity suggesting management confidence
- Biopharmaceutical sector offers potential for high returns if pipeline succeeds
Risks
- Negative stockholders' equity represents technical insolvency risk
- Insufficient cash runway (<18 months at current burn rate)
- Pre-revenue stage with no demonstrated commercial viability
- Extreme negative ROA indicates severe value destruction
- Liabilities exceed assets by 4.6M, creating balance sheet crisis
- Operating losses accelerating despite YoY improvement
- Critical liquidity crisis with current ratio of 0.30x
Key Metrics to Watch
- Cash balance and monthly burn rate trajectory
- Achievement of clinical development milestones
- Equity financing or capital raise announcements
- Operating expense management and cash runway extension
Financial Metrics
Revenue
N/A
Net Income
-15.4M
EPS (Diluted)
$-72.94
Free Cash Flow
-1.5M
Total Assets
3.9M
Cash
1.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-393.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.30x
Quick Ratio
0.30x
Debt/Equity
N/A
Debt/Assets
216.2%
Interest Coverage
-972.49x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T04:36:10.400521 |
Data as of: 2025-09-30 |
Powered by Claude AI